HCW BIOLOGICS INC. - C

U.S. Patent Issued to HCW Biologics for Foundational Platform Technology

03 Aug 2022 07:15:00 By Nasdaq GlobeNewswire

HCW Biologics to Participate in H.C. Wainwright Annual Global Life Sciences Conference May 23 – 25, 2022

23 May 2022 07:30:00 By Nasdaq GlobeNewswire

HCW Biologics Reports First Quarter 2022 Financial Results and Recent Business Highlights

13 May 2022 07:15:00 By Nasdaq GlobeNewswire

HCW Biologics to Showcase Two Novel Groups of Fusion Molecules Created with Proprietary and Versatile TOBI™ Platform At the 105th Annual Meeting of the American Association of Immunologists

05 May 2022 07:30:01 By Nasdaq GlobeNewswire

HCW Biologics’ CEO Hing C. Wong, Ph.D., to be Featured Speaker at the Third Annual International Conference on Cell and Experimental Biology 2022

19 Apr 2022 07:33:00 By Nasdaq GlobeNewswire

HCW Biologics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights for 2021

28 Mar 2022 07:00:00 By Nasdaq GlobeNewswire

HCW Biologics to Present at 2022 Virtual Growth Conference Sponsored by the Maxim Group and M-Vest

24 Mar 2022 08:00:01 By Nasdaq GlobeNewswire

Masonic Cancer Center at the University of Minnesota Receives FDA Clearance to Proceed with Phase 1 Clinical Trial in Solid Tumors for HCW9218, HCW Biologics’ Novel Bifunctional Fusion Protein

24 Jan 2022 07:00:01 By Nasdaq GlobeNewswire

HCW Biologics Inc. Announces its Lead Product Candidate Shown to Augment Anti-Tumor Activity and Reduce Side Effects of Chemotherapy Regimens

20 Jan 2022 08:00:03 By Nasdaq GlobeNewswire

HCW Biologics’ Founder and CEO Dr. Hing C. Wong Participating in Cambridge Healthtech Institute’s Annual PepTalk Conference 2022

19 Jan 2022 08:00:01 By Nasdaq GlobeNewswire

HCW Biologics to Participate in H.C. Wainwright BioConnect Conference January 10 – 13, 2022

06 Jan 2022 07:33:00 By Nasdaq GlobeNewswire

HCW Biologics’ Founder and CEO Dr. Hing C. Wong Named Weaver H. Gaines Entrepreneur of the Year

13 Dec 2021 07:31:00 By Nasdaq GlobeNewswire

HCW Biologics Reports Third Quarter Financial Results and Recent Business Highlights

12 Nov 2021 07:00:02 By Nasdaq GlobeNewswire

HCW Biologics Receives FDA Clearance to Proceed with Phase 1b Clinical Trial for Immunotherapeutic HCW9218 for Pancreatic Cancer

28 Oct 2021 07:00:01 By Nasdaq GlobeNewswire

HCW Biologics Showcases Scientific Paper in Molecular Therapy Highlighting Potential of HCW9218 as Novel, Bifunctional Cancer Immunotherapeutic

24 Aug 2021 07:32:00 By Nasdaq GlobeNewswire

HCW Biologics’ Article Published in Cancer Immunology Research Validates Novel Tissue Factor Scaffold Fusion Protein (TOBI™) Discovery Platform

17 Aug 2021 07:32:00 By Nasdaq GlobeNewswire

HCW Biologics Reports Second Quarter Financial Results and Recent Business Highlights

13 Aug 2021 07:10:00 By Nasdaq GlobeNewswire

HCW Biologics Inc. Announces Closing of $56.0 Million Initial Public Offering

22 Jul 2021 16:05:00 By Nasdaq GlobeNewswire

HCW Biologics Inc. Announces Pricing of $56.0 Million Initial Public Offering

19 Jul 2021 18:39:57 By Nasdaq GlobeNewswire